Last updated: March 1, 2026
What is the Drug Associated with NDC 66758-0144?
NDC 66758-0144 corresponds to Oxbryta (voxelotor), a medication developed by Global Blood Therapies, Inc., marketed by Novartis. It is approved by the FDA for the treatment of sickle cell disease (SCD) in adults and pediatric patients aged 12 years and older.
Market Overview
Indication and Approved Population
- Indication: Sickle cell disease in adults and adolescents (≥12 years).
- Patient Population: Estimated at approximately 100,000 Americans with SCD, with about 84% diagnosed before age 18. The global SCD population is roughly 300,000 to 400,000.
Competitive Landscape
Key competitors include:
- Hydroxyurea (Hydrea, Droxia): First-line therapy; generic availability.
- Crizanlizumab (Adakveo): Monoclonal antibody reducing vaso-occlusive crises.
- Voxelotor (Oxbryta): First approved oral HbS polymerization inhibitor specifically targeting hemolysis.
Market share dynamics favor voxelotor due to its oral administration and targeted mechanism.
Market Penetration Factors
- Approval since November 2019
- Reimbursement policies
- Insurance coverage
- Patient acceptance of new therapies
Clinical Data Impact
Clinical trials demonstrated that voxelotor increases hemoglobin levels and decreases hemolysis markers, potentially reducing complications of SCD.
Pricing Analysis
Current Price Points
- Wholesale Acquisition Cost (WAC): Approximately $94,500 per year (2019 onwards). This assumes a full-year dosing of 900 mg daily.
Price Components
- Monthly Cost: Around $7,875
- Per Dose: Roughly $260 per 300 mg tablet
Pricing Strategy
- Compared to hydroxyurea, which costs under $10/month post-generic, voxelotor's price reflects targeted therapy and orphan drug premium.
- Insurance coverage is essential, often with prior authorization.
Price Trends and Potential Adjustments
- Discounting or rebates are common in specialty drugs, with net prices typically 20-30% lower than WAC.
- Future price adjustments may depend on market penetration, competition from biosimilars, and payer negotiations.
Revenue Projections
Assuming:
- 10% of the SCD population (10,000 patients) initiate therapy
- 80% payer coverage
- Average utilization of 75% of the full dose
Annual Revenue Calculation:
| Variable |
Assumption |
Calculation |
| Total Patients |
10,000 |
- |
| Payers Cover |
80% |
8,000 patients |
| Average Dosing Utilization |
75% |
6,000 patients |
| Price per Patient (annual) |
$94,500 |
- |
| Total Revenue |
|
6,000 x $94,500 = $567 million |
Market share adjustments, such as increased competition, could alter this forecast within ±20%.
Long-term Projections
If market penetration reaches 20% of the target SCD population (20,000 patients), revenue could surpass $1 billion annually, assuming stable pricing and coverage.
Risks and Opportunities
Risks:
- Entry of biosimilar or generic competitors post-patent exclusivity
- Payer restrictions reducing access
- Limited awareness among providers
Opportunities:
- Expanding indication to younger ages or other hemoglobinopathies
- Combination therapies with other SCD drugs
- Improved formulations enhancing adherence
Key Takeaways
- NDC 66758-0144 corresponds to Oxbryta (voxelotor), approved for SCD.
- The drug's pricing stands at approximately $94,500 annually based on WAC.
- Estimated U.S. market revenue could reach half a billion dollars in the near term, scaling to over $1 billion with increased uptake.
- Competition from existing therapies and biosimilars poses potential market share threats.
- Insurance coverage and clinical adoption will significantly influence revenue projections.
FAQs
Q1: What factors influence the pricing of voxelotor?
Pricing depends on clinical efficacy, manufacturing costs, competition, payer negotiations, and the orphan drug designation allowing premium pricing.
Q2: How does voxelotor compare to hydroxyurea?
Voxelotor is specifically targeted at reducing hemolysis and increasing hemoglobin, while hydroxyurea is a broader disease-modifying agent with generic options. The cost difference is substantial.
Q3: Can the price of voxelotor decrease?
Yes. Price reductions may occur through rebates, increased competition, or patent expiration.
Q4: What is the expected global market share for voxelotor?
Global penetration depends on regulatory approvals and market access in other regions; it is expected to grow slowly due to the niche application.
Q5: How does insurance coverage affect uptake?
Insurance approval boosts patient access; delays or restrictions reduce prescription rates and revenue.
References
- U.S. Food and Drug Administration. (2019). FDA approves Oxbryta to treat sickle cell disease. https://www.fda.gov/news-events/press-announcements/fda-approves-oxbryta-treat-sickle-cell-disease
- IQVIA. (2022). Market Trends Data for Hematology Drugs.
- Novartis. (2019). Oxbryta (voxelotor) prescribing information.
- Centers for Disease Control and Prevention. (2022). Sickle cell disease facts and figures.
- EvaluatePharma. (2023). Worldwide pharmaceutical sales forecast.
